These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 9001898

  • 1. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes.
    Ruggenenti P, Remuzzi G.
    Exp Nephrol; 1996; 4 Suppl 1():53-60. PubMed ID: 9001898
    [Abstract] [Full Text] [Related]

  • 2. Prognosis of diabetic nephropathy: how to improve the outcome.
    Remuzzi G, Ruggenenti P.
    Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S49-53. PubMed ID: 9649960
    [Abstract] [Full Text] [Related]

  • 3. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S, Aurell M.
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED, Preddie DC.
    Ethn Dis; 2002 Nov; 12(4):S3-49-52. PubMed ID: 12477155
    [Abstract] [Full Text] [Related]

  • 9. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 10. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC, Hörl WH.
    Wien Med Wochenschr; 2001 Mar; 151(7-8):160-4. PubMed ID: 11450164
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Diabetes, nephropathy, and the renin system.
    Hollenberg NK.
    J Hypertens Suppl; 2006 Mar; 24(1):S81-7. PubMed ID: 16601578
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G, Allen TJ, Gilbert RE, Hammond J, Cooper ME, Campbell DJ, Raffaele J.
    J Diabetes Complications; 1995 Mar; 9(4):308-14. PubMed ID: 8573754
    [Abstract] [Full Text] [Related]

  • 18. Glomerular protein trafficking and progression of renal disease to terminal uremia.
    Benigni A, Remuzzi G.
    Semin Nephrol; 1996 May; 16(3):151-9. PubMed ID: 8734458
    [Abstract] [Full Text] [Related]

  • 19. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
    Parving HH.
    Diabetologia; 1998 Jul; 41(7):745-59. PubMed ID: 9686914
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.